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Wnt signaling plays a key role in regulating bone remodeling. In vitro studies suggest that sclerostin’s
inhibitory action on Lrp5 is facilitated by the membrane-associated receptor Lrp4. We generated an
Lrp4 R1170W knockin mouse model (Lrp4KI), based on a published mutation in patients with high
bone mass (HBM). Lrp4KI mice have an HBM phenotype (assessed radiographically), including
increased bone strength and formation. Overexpression of a Sost transgene had osteopenic effects
in Lrp4-WT but not Lrp4KI mice. Conversely, sclerostin inhibition had blunted osteoanabolic effects
in Lrp4KI mice. In a disuse-induced bone wasting model, Lrp4KI mice exhibit significantly less bone
loss than wild-type (WT) mice. In summary, mice harboring the Lrp4-R1170Wmissense mutation reca-
pitulate the human HBM phenotype, are less sensitive to altered sclerostin levels, and are protected
from disuse-induced bone loss. Lrp4 is an attractive target for pharmacological targeting aimed at
increasing bone mass and preventing bone loss due to disuse.1Department of Anatomy and
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Wnt signaling plays a key role in regulating bone modeling and remodeling. Perturbations in the Wnt
pathway can have profound effects on bone properties, in both positive (osteosclerosis) and negative (os-
teopenia) directions. Those effects are most easily appreciated by the handful of skeletal conditions that
are directly linked to mutations in the Wnt pathway. For example, patients with loss-of-function mutations
in theWnt co-receptor low-density lipoprotein receptor-related protein 5 (Lrp5) present with very low bone
mass and density, a condition known as Osteoporosis Pseudoglioma. Conversely, patients with gain-of-
function mutations in LRP5 can present with very high bone mass and density, a condition known as
Endosteal Hyperostosis (Little et al., 2002; Boyden et al., 2002; Costantini et al., 2017; Van Wesenbeeck
et al., 2003). The Lrp5 inhibitor sclerostin (Sost) is another key regulator of bone properties. Patients with
homozygous loss-of-function mutations in Sost have sclerosteosis, characterized by dramatically increased
bone mass and density (Balemans et al., 2001, 2002; Staehling-Hampton et al., 2002).
The skeletal phenotypes associated with mutations in the Wnt pathway, particularly the high-bone-mass
causing mutations, have highlighted the potential utility of targeting Wnt pathway components for thera-
peutic benefit in patients with low bone mass. Specifically, the observation of increased bone mass in
patients with sclerosteosis and the relatively restricted expression of Sost to bone tissue suggest that scle-
rostin targeting is an attractive strategy for improving bone properties. In both pre-clinical animal models
and human clinical trials, treatment with antibodies raised against sclerostin has consistently improved
bone properties beyond any currently approved therapies. At the time of this writing, the sclerostin mono-
clonal antibody Evenity was very recently approved in the United States and Japan for treatment of oste-
oporotic patients at high risk of fracture. A better understanding of sclerostin’s mechanism of action might
reveal other targets or accessory agents that could make this approach safer, more efficacious, or more
cost effective.
One of the more recent discoveries regarding sclerostin biology is the observation that sclerostin’s inhib-
itory action on Lrp5 is facilitated by the membrane-associated receptor Lrp4. Lrp4 is most widely studied
for its role in the neuromuscular junction (NMJ), where it serves as a receptor for motor neuron-derived
agrin/Wnt and facilitates acetylcholine receptor clustering on the myocyte. Loss of Lrp4 prevents the for-
mation of NMJs and, consequently, leads to perinatal lethality (Barik et al., 2014). However, Lrp4 also playsiScience 20, 205–215, October 25, 2019 ª 2019 The Author(s).
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Figure 1. Generation of Lrp4 R1170W Knockin Mouse Model
(A) Mouse Lrp4 genomic DNA schematic, showing the exon 25/intron 25 targeting area. A CRISPR/Cas9 approach was
used to replace a 135-bp sequence with a donor oligo containing a C/T mutation at position 1 of aa1170, as well as two
silent mutations in the flanking codons to facilitate genotyping.
(B) PCR products from exon 25 were sequenced to confirm mutations. A representative Sanger electropherogram from a
heterozygous knockin mouse shows equal expression of the three individual base substitutions in the three consecutive
codons.
(C)Western blot of cortical bone tissue protein extract from 6- to 8-week-old Lrp4WT and Lrp4KI mice, immunoreacted for
Lrp4 (240kDa), indicating comparable Lrp4 protein expression levels in Lrp4KI versus Lrp4 WT mice. Lane loading
equivalency was assessed by stripping and reprobing for the focal adhesion protein vinculin (lower panel) and via
Ponceau-S staining of the membrane for total protein before blotting (right panel). Two control lanes were removed
between molecular markers and wild-type lanes for clarity.a role in bone metabolism, and patients with certain NMJ-sparing missense mutations in LRP4 exhibit a
sclerosteosis-like phenotype (SOST2; see Leupin et al., 2011). Deeper investigation revealed a sclero-
stin-interacting pocket in the central domain of the receptor’s third b-propeller (3bCD), mutation of which
(e.g., R1170W, R1170Q, and W1186S) does not appear to alter the Agrin/LRP4/MuSK axis. However, these
3bCD mutations are proposed to impair interaction with sclerostin and, ultimately, sclerostin’s efficacy in
inhibiting Lrp5/6. Accordingly, this domain of Lrp4 represents a potential opportunity to augment the scle-
rostin-Lrp5/6 interaction for therapeutic value (Chang et al., 2014).
In addition to regulating baseline bonemass and bonemetabolism, theWnt signaling pathway is critical for
orchestrating the response of bone tissue to changes in the mechanical environment. Reduced mechanical
input to bone (e.g., disuse) leads to decreases in bone mass and increased bone resorption. Conversely,
increased mechanical stimulus to bone (e.g., loading) leads to increases in bone mass and osteogenesis.
Sost/sclerostin plays a significant regulatory role in both of these phenomena (Tu et al., 2012; Lin et al.,
2009), but it is unclear whether and how Lrp4 modifies sclerostin action in these processes.
In this communication, we further elucidate the interaction between Lrp4 and sclerostin using a new Lrp4
3bCD mutant mouse model (R1170W knockin). We examine the role of 3bCD in sclerostin efficacy by over-
expressing or neutralizing sclerostin in Lrp4 R1170Wmice using genetic and pharmacologic tools. We also
probe the role of Lrp4 in disuse mechanotransduction, to evaluate its translational potential as bone-
sparing therapy for disuse. Our results suggest that Lrp4 plays a significant role in bone metabolism and
likely does so through interaction with sclerostin. Furthermore, Lrp4 might serve as a high-yield target
for the development of compounds that can protect skeletal integrity during mechanodeprivation.
RESULTS
Mice with the Lrp4 R1170W Mutation Exhibit Increased Bone Mass
To better understand the cellular mechanisms driving the high bone mass (HBM) phenotype in patients
with SOST2, we generated a mouse model recapitulating the mutation found in one of the families
(LRP4 R1170W) using a CRISPR/Cas9 approach (Figure 1A). A C/T point mutation was knocked into the
first position of the codon for aa.1170 (confirmed by Sanger sequencing, Figure 1B), which resulted in
the predicted Arg/Trp amino acid substitution. Western blotting for Lrp4 indicated that the missensemu-
tation had no effect on Lrp4 protein expression in cortical bone (Figure 1C).206 iScience 20, 205–215, October 25, 2019
Figure 2. Lrp4KI Mice Have a High Bone Mass Phenotype
(A and B) (A) Whole-body bone mineral density (BMD) was significantly elevated in female Lrp4KI mice versus WT (+/+) and heterozygous (+/KI) littermates,
despite (B) normal body mass.
(C–G) (D–G) Trabecular bone volume fraction (Tb.BV/TV) in the distal femur and fifth lumbar vertebra (L5) and cortical thickness (Ct.Th) in the mid-diaphyseal
femur were significantly increased in 18-week-old female Lrp4KI mice compared with WT (+/+) and heterozygous (+/KI) littermates, despite (C) normal femur
length. (E) The center panel depicts mCT reconstructions from the midshaft femur (upper), distal femur (middle) and vertebral body (lower) from
representative +/+, +/KI, and KI/KI mice. Scale bar, 1 mm.
(H–J) Peripheral quantitative computed tomography (pQCT) measurements through the proximal tibia of 8-week-old female +/+, +/KI, and KI/KI mice reveal
an increase in trabecular BMD and cortical BMC among KI/KI mice.
(K–M) Mechanical testing of femora from 18-week-old female +/+, +/KI, and KI/KI mice reveal increased ultimate force and energy to ultimate force (FU)
among knockin mice.
(N–P) Parietal thickness and planar area of foramen ovale in 18-week-old female +/+ and KI/KI female crania were not affected by themutation. Male data are
presented in Table S2. For (A) and (B), *p < 0.05 for comparison to +/+ by repeatedmeasures ANOVA; for (C)–(P), *p < 0.05 for comparison to +/+mice, using
one-way ANOVA followed by Fisher’s protected least significant differences (PLSD) post hoc tests. n = 10/group. Data are presented as means GSEM.
See also Figure S1, Tables S1 and S2.We next sought to determine whether the Lrp4-R1170W knockin mice (hereafter referred to as Lrp4KI) reca-
pitulate the skeletal phenotype reported for patients with SOST2 with centrally located third b-propeller
missense mutations (R1170W, R1170Q, W1186S). The Lrp4KI colony was expanded, along with wild-type
(WT) and heterozygous littermates, and subjected to a battery of skeletal phenotyping endpoints. The mu-
tation did not affect body mass or femur length (Figures 2B-2C), but Lrp4KI mice displayed significant in-
creases in dual-energy X-ray absorptiometry (DEXA)-derived whole-body bone mineral density (BMD)
and content (BMC) as early as 6 weeks of age (Figure 2A, Tables S1 and S2). At 18 weeks of age, mCT-
derived femur and vertebral cortical and cancellous bone mass were significantly increased in Lrp4KI asiScience 20, 205–215, October 25, 2019 207
compared with both WT and heterozygous littermates (Figures 2D–2G and Tables S1 and S2). pQCT-
derived cortical BMC and trabecular BMD in the proximal tibia of 8-week-old Lrp4KI mice were also signif-
icantly elevated (Figures 2H–2J). Three-point bending tests conducted on femora from 18-week-old mice
revealed improved biomechanical properties in Lrp4KI mice, including significantly increased ultimate
force and energy absorption (Figures 2K–2M).
Patients with SOST2 display calvarial sclerosis, which is recapitulated in Lrp4KI mice, although much more
robustly in male mice (Table S2) compared with female mice (Figures 2N–2P). We previously reported ste-
nosis of cranial nerve foramina in the basicranium of Lrp5-HBM and Sost knockout mouse models (Niziolek
et al., 2015), which, at least in patients with sclerosteosis, can lead to cranial nerve deficits. However, the
foramen ovale area was not significantly affected by the Lrp4KI mutation (Figure 2P). Although dental anom-
alies have not been reported in patients with SOST2, we also found dental anomalies in Lrp4KI mice,
including supernumerary incisors andmolars, with altered cuspmorphology (Figure S1). In summary, Lrp4KI
mice recapitulate the human HBM phenotype associated with SOST2.
Lrp4KI Mice Have Increased Bone Formation, Sclerostin Expression, and Mildly Impaired
Muscle Function
Understanding of the mechanism of action (increased osteoanabolism or decreased osteocatabolism) for
the observed HBM phenotype in Lrp4KI mice can guide translational applications for Lrp4 targeting. To
investigate cellular activity, we performed quantitative cortical bone histomorphometry on Lrp4KI and
WT control mice. Bone formation parameters were increased in 16- to 17-week-old but not 8- to 11-
week-old mutant mice (Figures 3A–3G). No changes in the resorption marker CTx were detected in
8-week-old wild-type or Lrp4KI mice (Figure 4H). Taken together those observations suggest that the
increased bone mass observed in Lrp4KI mice is due to increased osteoblast-mediated bone formation,
positioning Lrp4 as a target for anabolic action in bone.
Lrp4 has been proposed to serve as a sequestering protein for sclerostin, where it might serve as a molec-
ular net to keep sclerostin levels high in the perimembrane region of bone cells (Fijalkowski et al., 2016).
Serum levels of sclerostin were significantly greater in Lrp4KI mice than in WT and heterozygous mice (Fig-
ure 3I), which is consistent with patient data (Leupin et al., 2011) and supports the premise that mutant Lrp4
has an impaired ability to retain sclerostin at the cell surface. However, cortical bone tissue lysates from
Lrp4KI mice yielded greater levels of sclerostin than lysates from WT mice (Figure 3H). That observation
runs counter to the proposal that osteocytes with mutant Lrp4 are less efficient at retaining sclerostin
locally, but it could also be explained by increased Sost expression in response to impaired Wnt inhibition
(Taylor et al., 2018; Holdsworth et al., 2018).
Lrp4 is critical for NMJ formation and muscle function, where it serves as a receptor for motoneuron-
derived Agrin, triggering interaction with MuSK (Shen et al., 2015). Mutations in the third b-propeller of
Lrp4 can affect Agrin and MuSK binding (Ohkawara et al., 2014), so we performed in vivo muscle force
testing in 10-week-old female WT and Lrp4KI mice (Figure 3J) to determine whether muscle function was
affected by the R1170W missense mutation. Muscle mass, time to maximum torque, and half relaxation
time were not different between WT and Lrp4KI mice, but maximum torque was significantly lower in Lrp4KI
mice (Figures 3K–3M). However, a change inmuscle function does not explain the HBMphenotype in Lrp4KI
mice since the mutation was associated with reduced rather than enhanced muscle forces on the skeleton.
In summary, Lrp4KI mice have HBM owing to increased anabolic activity, despite increased local and sys-
temic sclerostin and compromised muscle function.
Overexpression of Sost in Bone Tissue Causes Osteopenia in WT but Not Lrp4KI Mice
Some reports suggest that Lrp4 acts as a facilitator of sclerostin inhibition of Lrp5/6, a proposition that is
supported by direct interaction between the Lrp4 third b-propeller and sclerostin and by suppression of
sclerostin-mediated Wnt inhibition by Lrp4 knockdown (Leupin et al., 2011). To determine whether
compromise of the sclerostin-Lrp4 interaction can account for the HBMphenotype of Lrp4KI, we bred Lrp4KI
mice to transgenic mice that overexpress human Sost in osteocytes (8kbDmp1-hSost). As expected, whole-
body BMD and BMC were decreased in Lrp4 WT mice overexpressing Sost, but Lrp4KI mice were unaf-
fected by Sost overexpression (Figures 4A and Tables S3 and S4). Lrp4KI mice were protected from the
osteopenic effects of Sost overexpression in the cancellous compartment of both the femur and spine (Fig-
ures 4B–4D), but the protective effects in the cortical compartment could not be evaluated because Lrp4208 iScience 20, 205–215, October 25, 2019
Figure 3. Lrp4KI Mice Have Increased Bone Formation, Increased Circulating and Local Sclerostin, and Reduced
Skeletal Muscle Function
(A–G) (A) Quantitative endocortical bone histomorphometry of the midshaft femur of 18-week-old +/+, +/KI, and KI/KI female
mice, measured using labels injected at 8 (orange) and 11 (red) weeks of age (B–D), and again using labels injected at 16 (green)
and 17 (red) weeks of age (E–G), indicate a significant increase in the bone formation parameters mineralizing surface (MS/BS),
mineral apposition rate (MAR), and bone formation rate (BFR/BS) at the later time point. Scale bar 500 mm.
(H)Western blot of cortical bone tissue protein extract from 6- to 8-week-old Lrp4WT and Lrp4KI mice, immunoreacted for
sclerostin (30 kDa), indicating increased sclerostin protein expression levels in Lrp4KI versus Lrp4 WTmice. Lane loading
equivalency was assessed by Ponceau-S staining of the membrane for total protein before blotting (right panel).
Molecular weight markers were moved to right side of blot for clarity with Ponceau-S staining labeling.
(I) Serum sclerostin was also significantly elevated in the circulation of Lrp4 KI mice, compared with +/+ and +/KI mice.
(J–M) (J) In vivomuscle function of the anterior compartmentmusculature (left panel) in 10-week-old femalemice revealed
a deficiency in maximum torque (K), but not the time to maximum torque (L) or half muscle relaxation time (M), among
Lrp4KI mice, compared withWTmice. For (B)–(I), p < 0.05 for comparison to +/+mice, using one-way ANOVA followed by
Fisher’s PLSD post hoc tests; for (K)–(M), *p < 0.05 for comparison to +/+ mice by repeated measures ANOVA.
n = 6/group (B–G); 3–8/group (H–I); and 9–10/group (K–M). Data are presented as means GSEM.WT mice did not manifest a Sost transgene effect when evaluated by mCT (Figure 4E) or bone formation
parameters (Figures 4F and 4G). The Sost transgene had no effect on the resorption marker CTx in WT
mice. CTx was slightly but significantly suppressed in Lrp4KI mice carrying the Sost transgene (Figure 4H).iScience 20, 205–215, October 25, 2019 209
Figure 4. Lrp4KI Mice Are Protected from the Osteopenic Effects of Sost Overexpression
(A) Whole-body bone mineral density (BMD) in female Lrp4+/+ mice was significantly reduced by the Dmp1-hSost transgene, which induces Sost
overexpression in late-stage osteoblasts and osteocytes, whereas Lrp4KI mice maintained high BMD regardless of Dmp1-hSost presence.
(B–E) (B–D) Trabecular bone volume fraction (Tb.BV/TV) in the distal femur and fifth lumbar vertebra (L5) were significantly reduced in 17-week-old female
Lrp4 WT that carried the hSost transgene but not in Lrp4KI mice that carried the hSost transgene. Scale bar, 1 mm. (E) Cortical thickness (Ct.Th) was not
affected by the hSost transgene in either Lrp4 genotype.
(F and G) Quantitative endocortical bone histomorphometry of the tibial cortex (I), calculated from 16 to 17 weeks, revealed no effect of the transgene on the
bone formation parameters mineralizing surface (MS/BS) bone formation rate (BFR/BS) in either Lrp4 genotype. Scale bar 250 mm.
(H) The serum resorptionmarker C-terminal telopeptide (CTx) was reduced by the hSost transgene in Lrp4mice, but not wild-typemice. Data frommalemice
are in Table S4. For (A), *p < 0.05 by repeated measures ANOVA for within Lrp4 genotype comparison of transgene presence, n = 8–10/group. For (C)–(H),
data were tested using two-way ANOVA with Lrp4 genotype and the Sost transgene as main effects. Inset at the top of each graph indicates significance of
the main effects and interaction (# = Lrp4 genotype p < 0.05; @ = Dmp1-hSost p < 0.05; y = interaction p < 0.05). When at least one term was significant,
Fisher’s PLSD post hoc tests were conducted and are indicated as *p < 0.05. For (C)–(E), n = 8–10/group. For (F) and (G), n = 4–6/group. For (H), n = 6–7/
group. Data are presented as means GSEM.
See also Tables S3 and S4.In summary, the otherwise bone-suppressive effects of excessive sclerostin in bone were largely absent in
Lrp4KI mice, suggesting that the R1170W mutation confers resistance to the inhibitory effects of sclerostin
in vivo.
Inactivation of Sclerostin Elicits a Blunted Osteogenic Effect in Lrp4KI Mice
In the previous section we evaluated the ability of Lrp4KI mice to maintain high bone mass in the presence
of excessive sclerostin. Next, we evaluated the contraposition regarding the sclerostin-Lrp4 interaction,
i.e., whether Lrp4KI mice can elicit a full anabolic response when sclerostin is inactivated pharmacologically.
If the R1170W mutation mimics a sclerostin-depleted environment, sclerostin neutralization should have
minimal effects. Four weeks of treatment with sclerostin monoclonal antibody (Scl-mAb) increased
whole-body BMD significantly compared with saline treatment in both WT and Lrp4KI female mice, but
the antibody-induced BMD gain exhibited by Lrp4KI mice was only about half of that exhibited by WT
mice (Figure 5E). Large gains in mCT-derived parameters (trabecular and cortical bone mass in the femur
and spine) weremeasured amongWTmice in response to Scl-mAb, but a blunted response (roughly a third
to a half of WT gains, yet still significant) was observed in Lrp4KI mice (Figures 5A–5D). With the exception of
mineral apposition rate (MAR), Scl-mAb treatment increased bone formation parameters significantly in
WT mice but not in Lrp4KI mice (Figures 5F–5H, Table S5). In summary, the strong anabolic effects of scle-
rostin neutralization were compromised or absent in Lrp4KI mice, likely due to the mutation having similar
functional (i.e., redundant) effects as sclerostin inactivation.210 iScience 20, 205–215, October 25, 2019
Figure 5. Response to Pharmacologic Inhibition of Sost Is Blunted in Lrp4KI Mice
Cortical thickness (Ct.Th.) (A) and trabecular bone volume fraction (Tb.BV/TV) (B) in the mid-diaphyseal and distal femur
and fifth lumbar vertebra (L5) (C) were significantly increased in 16-week-old female Lrp4KI andWT (+/+) mice treated with
sclerostin monoclonal antibody (Scl-mAb), but the gains were more pronounced in WT mice.
(D) mCT reconstructions from the midshaft femur (upper) distal femur (middle) and vertebral body (lower) from
representative +/+ and KI/KI mice treated with vehicle () or Scl-mAb (+). Scale bar, 1 mm.
(E) Percent change in whole-body bone mineral density (BMD) during the 4-week antibody treatment period was greater
in WT mice compared with Lrp4KI mice.
(F–H) The periosteal bone formation parameters mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone
formation rate (BFR/BS) were significantly increased in WT but not Lrp4KI mice in response to sclerostin antibody. Scale
bar 100 mm. For all data panels, data were tested using two-way ANOVA with Lrp4 genotype and the Scl-mAb injection as
main effects. Inset at the top of each graph indicates significance of the main effects and interaction (# = Lrp4 genotype
p < 0.05; @ = Scl-mAb p < 0.05; y = interaction p < 0.05). When at least one term was significant, Fisher’s PLSD post hoc
tests were conducted and are indicated as *p < 0.05. For all panels, n = 6–10/group.
Data are presented as means GSEM. See also Table S5.Lrp4KI Mice Are Partially Protected from Disuse-Induced Bone Wasting
Bone is a highly mechanosensitive tissue, and previous studies highlighted the importance of canonical
Wnt signaling, particularly sclerostin, in this process. Mechanical disuse induces an increase in Sost expres-
sion, and Sost genetic deletion or sclerostin pharmacologic neutralization prevented disuse-induced bone
loss (Robling et al., 2016). Given our accumulating evidence that the Lrp4 R1170W mutation confers prop-
erties to bone tissue that are similar to sclerostin neutralization, we explored the role of Lrp4KI in response
to disuse mechanotransduction. Lrp4KI mice (12 weeks of age) were subjected to 4 weeks of unilateral me-
chanical disuse of the hindlimb using the Botulinum toxin-induced muscle paralysis model (Warner et al.,
2006), and the degree of bone wasting was evaluated radiographically. The paralyzed limb of WT mice lostiScience 20, 205–215, October 25, 2019 211
Figure 6. Lrp4KI Mice Are Partially Protected From Disuse-Induced Bone Loss
(A) Percent change in hindlimb bone mineral density (BMC) following 4 weeks of Botox-induced disuse.
(B and C) Percent difference (from contralateral limb) in trabecular bone volume fraction (Tb.BV/TV) in the proximal tibia
and cortical thickness (Ct.Th) in the mid-diaphyseal tibia were significantly greater in Botox-treated WT mice compared
with Botox-treated Lrp4KI mice.
(D) mCT reconstructions at the proximal tibia from representative +/+ and KI/KI mice treated with Botox (+) or vehicle ().
Scale bars, 1 mm. Data were tested using two-way ANOVA using Lrp4 genotype and Botox injection as main effects. Inset
at the top of each graph indicates significance of the main effects and interaction (# = Lrp4 genotype p < 0.05; @ = Botox
effect p < 0.05; y = interaction p < 0.05). When at least one term was significant, Fisher’s PLSD post hoc tests were
conducted and are indicated as *p < 0.05. For all panels, n = 9–10/group.
Data are presented as means GSEM. See also Table S6.10% BMD, but Lrp4KI mice did not lose BMD in response to Botox (Figure 6A). However, although bone
loss was spared in the paralyzed limb of Lrp4KI mice, we detected a significant failure to gain bone as was
observed in the saline-treated limb of Lrp4KI mice (Figure 6A). Proximal tibial trabecular bone mass was
significantly reduced by Botox in both WT and Lrp4KI mice, but the Lrp4KI mice lost roughly half as much
bone as WT mice in response to paralysis (Figures 6B and 6D). Cortical bone loss was significant in
Botox-treatedWTmice as expected, but paralyzed (Botox-treated) limbs from Lrp4KI mice exhibited no dif-
ference from saline-treated limbs (Figure 6C). Periosteal bone formation was nearly abolished in the para-
lyzed limbs of WT mice, but Lrp4KI mice maintained unparalyzed levels of MAR but not MS/BS or BFR
(Table S6). In summary, Lrp4KI mice exhibit less severe bone wasting in response to mechanical disuse212 iScience 20, 205–215, October 25, 2019
than WT mice, suggesting that pharmacologically targeting the third b-propeller of Lrp4 during a disuse
event might have therapeutic value in reducing bone loss.DISCUSSION
High bone mass (HBM)-causing mutations in genes coding for secreted or plasma membrane-bound Wnt
signaling components represent rare glimpses into molecular targeting opportunities to improve bone
health and fracture resistance in osteoporotic patients. Targets that can bemodulated to produce anabolic
action in the skeleton are particularly attractive, given the paucity of approved and pipeline osteoanabolic
agents. The identification of patients with a sclerosteosis-like condition harboring missense mutations in
LRP4 (Leupin et al., 2011) has furthered our understanding of accessory proteins involved in extracellular
Wnt inhibition and also provided additional avenues for therapeutic development. We engineered an or-
thologous mouse model to one of the HBM human families identified with an HBM-causing LRP4 missense
mutation, which yielded an HBM phenotype and provided a tool to study more mechanistic questions
beyond those suited to clinical studies (e.g., bone strength, tissue protein levels). We found that the
Lrp4 R1170W knockin mice recapitulate the skeletal phenotype observed in patients with SOST2 and
that the phenotype is driven largely by anabolic action.
Moreover, we were able to identify several additional traits associated with Lrp4 3bCD mutation that
have not been reported in patients with SOST2, including changes to the dentition (also observed in
other Lrp4 models [Ahn et al., 2017]), compromised muscle function, and increased levels of sclerostin
in osteocyte-enriched protein lysates from bone tissue. Conversely, we failed to find some traits in the
murine model that have been identified in patients (e.g., skull thickness, phenotype in the heterozygous
state). The reduction in muscle function in Lrp4KI mice is surprising. Certain missense mutations in the
third b-propeller of LRP4 (e.g., E1233K and R1277H) can cause congenital myasthenic syndrome
(CMS), a non-autoimmune disorder associated with progressive muscle weakness. CMS mutations
located on the outer edge of the third b-propeller impair Lrp4 interaction with both Agrin and
MuSK—key interactions for NMJ assembly and maintenance (Ohkawara et al., 2014). However, cell cul-
ture models show that overexpression of R1170W impairs Wnt signaling but has no effect on Agrin-
induced MuSK signaling, suggesting that centrally located missense mutations (e.g., R1170W) affect
Wnt but not Agrin/MuSK, whereas those located on the propeller edge have the inverse effect. Our
data do not identify a direct role for the R1170W mutation in regulating muscle function; other indirect
explanations (e.g., R1170W-induced increase in circulating sclerostin might impair muscle function)
cannot be ruled out.
Another interesting finding was the increased levels of sclerostin protein in bone extracts. Human patients
with LRP4 HBM (Fijalkowski et al., 2016), other mouse models of Lrp4 mutation (Xiong et al., 2015; Boudin
et al., 2017), and WT mice treated with Lrp4 neutralizing antibody (Chang et al., 2014) all have increased
levels of circulating sclerostin, which we confirmed in our R1170W model. Additionally, we also found
increased sclerostin protein in bone, which was surprising given (1) Lrp4’s purported role in retaining scle-
rostin at high levels in the local bone environment (which is presumably inhibited by the Lrp4 HBM muta-
tions) and (2) previous reports of decreased sclerostin in the osteocytes of Lrp4 knockin mice (R1170Q), as
assessed by immunohistochemistry (Boudin et al., 2017). One explanation for the increase in tissue sclero-
stin despite a lack of its primary retention mechanism (functional Lrp4) that is consistent with our previous
data is the self-regulation of sclerostin expression observed when sclerostin signaling is inhibited geneti-
cally or pharmacologically (Witcher et al., 2018).
Investigation of the interaction between Lrp4 and sclerostin has thus far been restricted to cell culture
experiments involving overexpression of various signaling components, which have the potential to be
problematic or misleading specifically in Wnt-related in vitro studies (Goel et al., 2012). We designed
in vivo experiments to better understand this interaction in a more physiologic context and did so using
excessive (hSost transgene) and depleted (Scl-Ab) sclerostin levels in Lrp4KI mice. Lrp4KI mice were
largely immune to changes in levels of sclerostin, where Lrp4KI mice overexpressing Sost failed to man-
ifest the osteopenic effects of the transgene and antibody-treated Lrp4KI failed to gain as much bone as
treated WT mice (although they did exhibit significant gains for several parameters). Although those ex-
periments do not prove a direct role in binding alterations, they do suggest that Lrp4 3bCD mutations
disturb the normal function of sclerostin in regulating bone mass in an in vivo context, both positively
and negatively.iScience 20, 205–215, October 25, 2019 213
To provide a translational context to Lrp4 clinical utility, we explored the role of Lrp4 in mediating disuse
osteoporosis. Wnt is a major regulator of mechanical signaling in bone, and we have previously reported
therapeutic effects of modulating Lrp5, Sost, and b-catenin in mechanical models (Niziolek et al., 2015; Ro-
bling et al., 2016, Bullock et al., 2019). Here, we evaluated the utility of Lrp4modulation in amuscle paralysis
model of bone loss. Lrp4KI mice exhibited significant protection from the bone wasting effects of lower limb
paralysis, suggesting that pharmacologic targeting of Lrp4 during or soon after a disuse injury might have
clinical benefit.
Recent regulatory approval for clinical use of sclerostin-neutralizing antibody in several countries (United
States, Japan, Canada, South Korea, Australia) has opened the door for widespread use of the first Wnt-
based therapy for bone health. Whether other components (e.g., Lrp4) alone or in conjunction with sclero-
stin targeting can provide additional benefits to patients remains to be determined, but Lrp4 targeting for
low bone mass states appears attractive from a preclinical perspective.
Limitations of the Study
The experiments performed have several limitations. First, the R1170W mutation was expressed globally.
Although that approach provided an orthologous model of the human patients with HBM-causing LRP4
mutations, it did not allow for cell-selective Lrp4 impairment as could be achieved with a conditional
knockin approach (Cui et al., 2011). Therefore, we do not know the cell type in which Lrp4 is most critical
for regulating sclerostin signaling. Second, we did not perform assays to assess sclerostin-Lrp4 interac-
tion in vivo, with and without the R1170W mutation. Those experiments have been performed in overex-
pression studies in vitro, but it is possible that, in the context of the in vivo environment, the interaction is
modified. Lastly, the Lrp4 mutant mice had altered Lrp4 function since conception. For translational pur-
poses, it would be more appropriate to understand the acute effects of disrupting the Lrp4-sclerostin
axis, as could be accomplished with neutralizing antibody or a small molecule inhibitor (Chang et al.,
2014).
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Figure S1
Figure S1. Lrp4KI mice display supernumerary teeth and altered molar cusp patterns.  Related 
to Figure 2. (A) µCT reconstructions from the occlusal view of the maxillary incisors illustrating a 
set of secondary incisors (blue arrow) distolingual to the primary set in WT (+/+) and Lrp4KI 
(KI/KI) mice.  (B and C) Close-up view of the mandibular dentition reveal extra incisors of 
varying development, and additional molar teeth on the distal end and lingual edge of the tooth 
row (blue arrows).  The molars also exhibit altered cusp pattern compared to those seen in the 
WT mice. 
 
Table S1. Radiographic and biomechanical analysis of female Lrp4 WT, HET and KI mice. Related to Figure 2. 
Wild-type (WT) R1170W/+ (HET) R1170W/R1170W (KI) 
Whole Body BMC (18 wk; g) 0.49 ± 0.1 0.47 ± 0.1 0.77 ± 0.1 
Body Weight (18 wk; g) 22.5 ± 1.3  22.1 ± 1.0 21.6 ± 2.2 
Femur length (mm) 15.2 ± 0.5 15.0 ± 0.2 15.3 ± 0.5 
Femur µCT 
Tb.N (1/mm) 2.16 ± 0.35 1.88 ± 0.30 * 2.84 ± 0.29 * 
Tb.Th (mm) 0.04 ± 0.01 0.04 ± 0.01 0.08 ± 0.01 * 
Tb.Sp (mm) 0.47 ± 0.08 0.55 ± 0.09 * 0.34 ± 0.05 * 
Tb.BMD (mg/cm3) 868 ± 40 879 ± 37 924 ± 34 * 
Tb.BMC (mg) 0.06 ± 0.12 0.02 ± 0.01 0.41 ± 0.18 * 
Ct.BMD (mg/cm3)  1.08 ± 0.02 1.08 ± 0.01 1.09 ± 0.01 * 
Ct.BMC (mg) 2.59 ± 0.42 2.60 ± 0.09 3.97 ± 0.70 * 
5th Lumbar µCT 
Tb.N (1/mm) 3.79 ± 0.8 3.69 ± 1.0 5.93 ± 1.1 * 
Tb.Th (mm) 0.05 ± 0.01 0.05 ± 0.01 0.08 ± 0.02 * 
Tb.Sp (mm) 0.26 ± 0.04 0.27 ± 0.05 0.17 ± .05 * 
Tb.BMD (mg/cm3) 871 ± 10 878 ± 15 871 ± 19 
Tb.BMC (mg) 0.28 ± 0.19 0.26 ± 0.14 0.79 ± 0.27 * 
Femur 3 point bending 
Stiffness (N/mm) 70.2 ± 12.2 67.9 ± 21.9 108.6 ± 2.6 * 
Energy to FU (mJ) 3.38 ± 1.3 4.10 ± 1.3 9.35 ± 1.6 * 
Energy to FF (mJ) 10.1 ± 2.6 9.6 ± 2.9 15.3 ± 4.7 * 
*p<0.05 for comparison to WT mice, using one-way ANOVA followed by Fisher’s PLSD post hoc tests. 
Table S2. Radiographic and biomechanical analysis of male Lrp4 WT, HET and KI mice. Related to Figure 2. 
Wild-type (WT) R1170W/+ (HET) R1170W/R1170W (KI) 
Whole Body BMD (18 wk; g/cm2) 70.1 ± 7.3 75.0 ± 8.0 91.6 ± 12.6* 
Whole Body BMC (18 wk; g) 0.54 ± 0.1 0.57 ± 0.1 0.76 ± 0.2* 
Body Weight (18 wk; g) 28.3 ± 0.8 27.68 ± 3.2 26.34 ± 2.2 
Femur length (mm) 15.4 ± 0.5 15.1 ± 0.2 15.2 ± 0.2 
Femur µCT 
Tb.BV/TV (unitless) 0.046 ± 0.02 0.046 ± 0.02 0.166 ± 0.05* 
Tb.N (1/mm) 3.193 ± 0.34 2.960 ± 0.27 3.722 ± 0.31* 
Tb.Th (mm) 0.05 ± 0.00 0.05 ± 0.01 0.07 ± 0.01* 
Tb.Sp (mm) 0.31 ± 0.03 0.34 ± 0.03 0.25 ± 0.03* 
Tb.BMD (mg/cm3) 887.3 ± 8.7 887.1 ± 21.6 901.5 ± 15.0* 
Tb.BMC (mg) 0.16 ± 0.10 0.17 ± 0.08 0.67 ± 0.23* 
Ct.BMD (mg/cm3)  1.06 ± 0.01 1.06 ± 0.00 1.07 ± 0.01* 
Ct.BMC (mg) 2.43 ± 0.23 2.57 ± 0.21 3.79 ± 0.28* 
Ct.Th (mm) 0.188 ± 0.01 0.195 ± 0.01 0.259 ± 0.02* 
5th Lumbar µCT 
Tb.BV/TV (unitless) 0.20 ± 0.03 0.18 ± 0.03 0.37 ± 0.15* 
Tb.N (1/mm) 4.75 ± 0.22 4.45 ± 0.23* 5.63 ± 1.15* 
Tb.Th (mm) 0.47 ± 0.01 0.048 ± 0.00 0.06 ± 0.02* 
Tb.Sp (mm) 0.20 ± 0.01 0.21 ± 0.013* 0.18 ± 0.06* 
Tb.BMD (mg/cm3) 881.7 ± 6.3 882.5 ± 9.5 870.9 ± 23.5 
Tb.BMC (mg) 0.342 ± 0.07 0.289 ± 0.07 0.586 ± 0.24* 
Femur 3 point bending 
Ultimate Force (N) 15.7 ± 2.9 16.9 ± 2.7 32.2 ± 4.4* 
Stiffness (N/mm) 56.9 ± 18.7 79.9 ± 20.8* 102.7 ± 51.2* 
Energy to FU (mJ) 4.94 ± 1.5 4.92 ± 1.2 11.96 ± 3.7* 
Energy to FF (mJ) 8.2 ± 2.8 11.7 ± 3.0* 16.6 ± 3.5 * 
Cranial Dimensions 
Skull Thickness (µm) 0.201 ± 0.08 ---- 0.295 ± 0.05 * 
Foramen Ovale Area (µm) 0.337 ± 0.18 ---- 0.273 ± 0.11 
*p<0.05 for comparison to WT mice, using one-way ANOVA followed by Fisher’s PLSD post hoc tests.
Table S3. Radiographic analysis and serum measurements in WT and Lrp4-KI female mice with 
and without a Dmp1-hSost transgene. Related to Figure 4. 
WT / NTG WT / Dmp1-hSost KI / NTG KI / Dmp1-hSost 
Whole Body BMC (17 wk; g) 0.473 ± 0.02 0.446 ± 0.04*  0.610 ± .0.07  0.639 ± 0.09 
Femur µCT 
Tb.N (1/mm)#@ 2.11 ± 0.36 1.24 ± 0.46* 2.42 ± 0.39 1.99 ± 0.48 
Tb.Th (mm) # 0.038 ± 0.006 0.046 ± 0.013 0.067 ±0.010 0.063 ± 0.014 
Tb.Sp (mm) #@† 0.49 ± 0.10 0.88 ± 0.26* 0.41 ± 0.07 0.53 ± 0.15 
Tb.BMD (mg/cm3) # 923.7 ± 24.6 926.1 ± 31.7 948.9 ± 20.1 939.3 ± 18.2 
Tb.BMC (mg) #@ 0.05 ± 0.02 0.01 ± 0.01* 0.28 ± 0.14 0.17 ± 0.11 
Ct.BMD (mg/cm3) #  1.07 ± 0.01 1.06 ± 0.02 1.09 ± 0.02 1.08 ± 0.02 
Ct.BMC (mg) # 2.44 ± 0.14 2.35 ± 0.14 3.56 ± 0.34 3.54 ± 0.46 
5th Lumbar µCT 
Tb.N (1/mm) # 3.72 ± 0.2 2.41 ± 0.8 5.41 ± 2.5 5.13 ± 1.2 
Tb.Th (mm) # 0.048 ± 0.003 0.056 ± 0.007 0.083 ± 0.011 0.085 ± 0.021 
Tb.Sp (mm) #† 0.263 ± 0.16 0.440 ± 0.12* 0.254 ± 0.23 0.204 ± 0.06 
Tb.BMD (mg/cm3) # 849.6 ± 14.1 863.1 ± 29.0 875.5 ± 3.83 877.9 ± 23.6 
Tb.BMC (mg) # 0.237 ± 0.02 0.133 ± 0.06 0.617 ± 0.36 0.703 ± 0.27 
Serum sclerostin (pg/µL) # 148.3 ± 19 131.2 ± 32 700.3 ± 291 778.8 ± 335 
Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype p<0.05; @=Dmp1-
hSost p<0.05; †=interaction p<0.05).  When at least one term was significant, Fisher’s PLSD post-hoc 
tests were conducted and are indicated as *p<0.05. 
Table S4. Radiographic analysis and serum measurements in WT and Lrp4-KI male mice with and 
without a Dmp1-hSost transgene. Related to Figure 4. 
WT / NTG WT / Dmp1-hSost KI / NTG KI / Dmp1-hSost 
Whole Body BMC (17 wk; g) 0.55 ± 0.10 0.55 ± 0.10 0.68 ± 0.08 0.72 ± 0.13 
Whole Body BMD (17 wk; g/cm2) 72.3 ± 8.6 73.2 ± 8.6 85.1 ± 7.3 89.9 ± 10.2 
Femur µCT 
Tb.BV/TV (unitless) #† 0.08 ±0.04 0.05 ± 0.02* 0.12 ± 0.03 0.17 ± 0.04* 
Tb.N (1/mm) #@† 3.34 ± 0.68 1.98 ± 0.25* 3.32 ± 0.27 3.56 ± 0.32 
Tb.Th (mm) #@ 0.050 ± 0.01 0.058 ± 0.01* 0.067 ± 0.00 0.072 ± 0.00 
Tb.Sp (mm) #@† 0.307 ± 0.06 0.514 ± 0.06* 0.287 ± 0.03 0.266 ± 0.03 
Tb.BMD (mg/cm3) #† 916.5 ± 19.6 925.0 ± 19.1* 925.9 ± 9.8 936.1 ± 14.7* 
Tb.BMC (mg) #† 0.345 ± 0.19 0.184 ± 0.10 0.471 ± 0.13 0.793 ± 0.32* 
Ct.BMD (mg/cm3) #  1.05 ± 0.03 1.04 ± 0.03 1.07 ± 0.01 1.08 ± 0.02 
Ct.BMC (mg) # 2.58 ± 0.51 2.53 ± 0.19 3.47 ± 0.17 3.84 ± 0.47 
Ct.Th (mm) # 0.198 ± 0.03 0.198 ± 0.01 0.243 ± 0.01 0.244 ± 0.03 
5th Lumbar µCT 
Tb.BT/TV (unitless) #@ 0.24 ± 0.09 0.08 ± 0.01* 0.43 ± 0.05 0.40 ± 0.14 
Tb.N (1/mm) #@† 4.99 ± 0.5 2.09 ± 0.3* 6.37 ± 0.7 5.29 ± 1.4 
Tb.Th (mm) # 0.051 ± 0.01 0.060 ± 0.01 0.072 ± 0.00 0.078 ± 0.01 
Tb.Sp (mm) #@† 0.190 ± 0.02 0.479 ± 0.07* 0.141 ± 0.03 0.198 ± 0.11 
Tb.BMD (mg/cm3) 874.5 ± 14.1 871.7 ± 11.3 856.4 ± 8.0 870.2 ± 17.3 
Tb.BMC (mg) #† 0.40 ± 0.16 0.13 ± 0.03* 0.58 ± 0.02 0.59 ± 0.22 
Serum sclerostin (pg/µL) # 143.3 ± 37 121.6 ± 23* 1007 ± 173 993.4 ± 109 
Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype p<0.05; @=Dmp1-
hSost p<0.05; †=interaction p<0.05).  When at least one term was significant, Fisher’s PLSD post-hoc 
tests were conducted and are indicated as *p<0.05 
Table S5. Histomorphometric analysis of cortical bone changes and serum sclerostin levels in WT and 
Lrp4-KI mice treated with sclerostin antibody. Related to Figure 5. 
WT / Veh WT / Scl-mAb KI / Veh KI / Scl-mAb 
Ec.MS/BS (%)@† 70.8±4.0 97.9±3.0* 82.9±9.2 92.1±3.6 
Ec.MAR (µm/day) 9.16±1.3 8.95±0.7 10.57±2.3 9.54±1.7 
Ec. BFR/BS (µm3/µm2/yr) 2381.7±451.8 3194.8±225.5 3160.3±542.0 3192.0±457.0 
Serum sclerostin (pg/µL) #@† 207.7±194.4 2971.5±44.7* 780.0±310.2 2942.1±45.0* 
Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype p<0.05; @=Scl-mAb 
p<0.05; †=interaction p<0.05).  When at least one term was significant, Fisher’s PLSD post-hoc tests 
were conducted and are indicated as *p<0.05 
Table S6. Histomorphometric analysis of cortical bone changes from muscle paralysis in WT and Lrp4-KI mice.
Related to Figure 6 
WT + Saline WT + Botox KI + Saline KI + Botox 
Ps. MS/BS (%)@ 65.9 ± 25.5 13.9 ± 9.6* 46.9 ± 16.5 12.3 ± 4.3* 
Ps. MAR (µm/day) @ 0.54 ± 0.17 0.0 ± 0.0* 0.56 ± 0.16 0.30 ± 0.22 
Ps. BFR/BS (µm3/µm2/day) @ 134.4 ± 79 0.0 ± 0.0* 93.1 ± 30 15.8 ± 14* 
Symbols indicate significance of the main effects and interaction (@=Scl-mAb p<0.05).  When at least one term 
was significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05 
Transparent Methods 
CONTACT FOR REAGANT AND RESOURCE SHARING 
Further information and requests for resources and reagants should be directed to and will be 
fulfilled by the Lead Contact, Alexander Robling (arobling@iupui.edu). 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 
Animals 
   Two different engineered mouse models were used.  The first is a new knock‐in model of a 
human patient with an Lrp4 mutation who presented with a sclerosteosis‐like phenotype 
(Leupin et al., 2011).  The orthologous mutation was generated in mice using a Crispr/cas9 
approach (Fig. 1A).  Briefly, a 135bp donor oligo was knocked into the 3’ half of Lrp4 exon 25 
and adjacent intron.  The donor oligo contained a c.3508C→T mutaƟon (plus several local 
nonsense mutations to facilitate genotyping) that results in an Arg1170Trp substitution 
(referred to as Lrp4KI).  The second engineered model—8kbDmp1‐hSOST transgenic mice—was 
utilized to generate overexpression of Sost in bone tissue (Tu et al., 2012). Briefly, a 12‐kb DNA 
fragment containing 8 kb of the 5′‐flanking region, the first exon, the first intron, and 17 bp of 
exon 2 of the murine Dmp1 gene was used to drive expression of a human SOST cDNA. The 
Dmp1‐hSOST mice and Lrp4‐R1170W knock‐in mice were on a fixed C57Bl/6J background. Male 
and female mice used in experiments ranged from 4‐18 weeks of age. All mice were maintained 
on‐site in accordance with Indiana University IACUC procedures.     
METHOD DETAILS 
Radiographic imaging 
Whole‐body DEXA scans were collected on isolfuorane‐anesthetized mice using a Faxitron 
UltraFocusDXA x‐ray densitometer (Faxitron Bioptics, Inc., Tucson, AZ). All mice were scanned 
between the ages of 4 to 18 weeks (longitudinal studies) or 3 days prior to the start of the 
experimental period and again immediately before euthanasia (disuse and antibody studies). 
From the whole‐body scans, areal bone mineral density (BMD) and bone mineral content (BMC) 
were calculated for the whole body (head and tail excluded) or limbs, depending on the study, 
using the Faxitron ROI tools.  
Collection of serial tibial pQCT measurements in live mice is described elsewhere (Robling et 
al., 2016). Briefly, a single slice through the proximal tibia, located 4 mm distal to the 
intracondryl eminance, was collected on isoflurane‐anesthetized mice using a Stratec x‐ray 
µScope (Stratec Inc.) at 70‐μm resolution. Slices were analyzed for bone mineral content and 
density using Stratec software in peel mode 2. 
After sacrifice, femora or tibiae were scanned, reconstructed, and analyzed on a Scanco µCT‐
35 desktop microcomputed tomographer (Scanco Medical AG, Brüttisellen Switzerland) as 
previously described (Niziolek et al., 2015).  Briefly, samples were scanned at 10‐μm resolution 
(femur, tibia and vertebra) or 20‐μm resolution (skull), 50‐kV peak tube potential and 151‐ms 
integration time. Standard output parameters related to cancellous and cortical bone mass, 
geometry, and architecture were measured and reported (Bouxsein et al., 2010). 
Mice received injections of demeclocycline (80 mg/kg), alizarin complexone (20 mg/mL) and 
calcein (10 mg/kg) at timepoints outlined in individual experiments. After µCT scanning, the 
fixed femora or tibiae were dehydrated in graded ethanols, cleared in xylene, and embedded in 
methylmethacrylate. Thick sections were cut from the midshaft using a diamond‐embedded 
wafering saw. Sections were ground and polished to ~30 μm, mounted and coverslipped, then 
digitally imaged on a fluorescent microscope. Periosteal and endocortical bone formation 
parameters were calculated by measuring the extent of unlabeled perimeter (nL.Pm), single‐
labeled perimeter (sL.Pm), double‐labeled perimeter (dL.Pm), and the area between the double 
labeling (dL.Ar) with Image‐Pro Plus software (MediaCybernetics Inc., Gaithersburg, MD). The 
derived histomorphometric parameters mineralizing surface (MS/BS), mineral apposition rate 
(MAR), and bone formation rate (BFR/BS) were calculated using standard procedures 
(Dempster et al., 2013). 
Molecular Mechanisms 
   Whole blood samples were collected from wild‐type, heterozygous and homozygous Lrp4 
mutant mice via cheek bleeding at 8 weeks of age. Approximately 150 μL of blood was collected 
into serum separator tubes (BD Microtainer), allowed to clot at room temperature for 20 
minutes, then centrifuged at 10,000g for 1 minute. Serum was removed and stored at −80°C 
until all samples were collected and assayed together. Serum sclerostin and C‐terminial 
telopeptide were measured by commercially available ELISA kits (Mouse/Rat SOST Quantikine 
ELISA, R&D Systems; RatLabs CTX‐I EIA, iDS) according to the manufacturer's instructions. 
Serum samples were measured in duplicate and averaged. 
   In vivo muscle function in Lrp4 mutant mice was evaluated using the 1305A Whole Mouse/Rat 
Test System (Aurora Scientific Inc., Aurora, ON, Canada) (Organ et al., 2016).  Electrodes were 
inserted subcutaneously near the tibial nerve in anesthetized mice, which were positioned in 
the instrument to allow ankle dorsiflexion force quantification.  Electrode placement and 
stimulation current were adjusted to achieve the maximum twitch response and then increased 
to ∼35 mA for plantarflexion to ensure supramaximal stimulation of the muscle fibers. The 
maximum isometric torque (N/m) was recorded for stimulation frequencies between 25 and 
300 Hz, with a pulse width of 0.2 ms and strain duration of 200 ms. Data were recorded using 
the Dynamic Muscle Control/Data Acquisition and Dynamic Muscle Control Data Analysis 
programs (Aurora Scientific Inc.).  
Immediately after sacrifice, mouse femur, tibia and fibula were dissected, stripped of soft 
tissue, and flushed to remove bone marrow. The remaining cortical bone tissue was 
immediately snap frozen, pulverized into powder, and solubilized in 800 µL of 4X SDS‐PAGE 
sample buffer.  The extract was heated at 95oC for 5 min, centrifuged at 14,000 x g for 10 min, 
and the supernatant was retained to run directly on gels.  
Approximately 20 µg of protein from each sample was run on a 6 % (Lrp4) or 4‐12% 
(sclerostin) polyacrylamide gradient gel (GenScript). Separated proteins were transferred to 
nitrocellulose overnight, stained with Ponceau‐S to visualize total protein and loading 
consistency. Membranes were blocked in 5% milk, then reacted with primary and HRP‐
conjugated secondary antibodies.  Bound HRP was reacted with ECL reagent (Amersham, ECL 
Prime Reagent).  Blots were imaged using an iBrightCL1000 (Invitrogen).   
Eight‐week‐old female mice (Lrp4+/+ or Lrp4KI/KI) were randomized to receive twice‐weekly 
subcutaneous injections of either sclerostin neutralizing antibody (Scl‐mAb) at 25 mg/kg or 
vehicle control for the next 4 weeks (n = 8 mice per genotype and treatment group). Scl‐mAb 
doses were adjusted weekly on the basis of body mass measurement. Animals were euthanized 
by CO2 inhalation when 12 weeks old, followed by tissue harvest.  
Parameters related to whole bone strength were measured using 3‐point bending tests (Cui et 
al., 2011). Each femur was loaded to failure in monotonic compression on a TestResources R‐
series controller, during which force and displacement were collected every 0.01 seconds. From 
the force/displacement curves, ultimate force and energy to failure were calculated using 
standard equations (Turner and Burr, 1993). 
Forty 12‐week‐old male mice were used for the Botox experiments, comprising 20 mice of 
each genotype (i.e., 20 Lrp4KI and 20 wild‐type).  Each genotype was further divided into control 
(saline‐injected) and Botox‐treated mice (n = 10/group).  The right hindlimb musculature 
(quadriceps, triceps surae, tibialis anterior, hamstrings) was injected with a total of 20 μL of 
Botulinum Toxin A (Botox; Allergan Inc., Irvine, CA), while the left hindlimb musculature was left 
alone and served as an internal control. Control mice received 20 μL injections of saline in the 
right hindlimb in an identical fashion as the Botox‐treated mice.  The injections (both Botox and 
saline) were repeated one week later to ensure paralysis in the Botox‐treated group ‐. Botox 
efficacy was qualitatively evaluated for each mouse every 3‐4 days, based on the inability of the 
treated mice to use the limb in normal cage locomotion. 
 
DATA AND SOFTWARE AVAILABILITY 
Original data can be found at http://dx.doi.org/doi:10.17632/9jm7ftmnsb.1 
QUANTIFICATION AND STATISTICAL ANALYSIS 
   Statistical analyses were conducted with SigmaPlot. Statistical details of each experiment can 
be found in the figure legends. Statistical significance was taken at p<0.05. Two‐tailed 
distributions were used for all analyses. Data are presented as means ± SEM. 
 
